Stock OBI ONDINE BIOMEDICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ondine Biomedical Inc.

Equities

OBI

CA68234M2058

Market Closed - London S.E.
Other stock markets
 09:15:45 03/05/2024 pm IST 		5-day change 1st Jan Change
6.6 GBX +28.78% Intraday chart for Ondine Biomedical Inc. +12.34% -24.57%
03/05 Ondine Biomedical shares rise on fundraise to advance Steriwave AN
03/05 Ondine Biomedical to Raise GBP3 Million Via Placing, Subscription MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
ONDINE BIOMEDICAL INC. Stock Ondine Biomedical Inc.
-24.57% 18.78M -
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.79% 184B
C+
MEDTRONIC PLC Stock Medtronic plc
-0.84% 108B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-3.75% 67.82B
A
DEXCOM, INC. Stock DexCom, Inc.
+3.45% 51.05B
B-
CENCORA, INC. Stock Cencora, Inc.
+9.04% 44.67B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.40% 41.78B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.21% 26.78B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+3.66% 26.59B
A-
TERUMO CORPORATION Stock Terumo Corporation
+15.23% 25.86B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-
  1. Stock Market
  2. Equities
  3. OBI Stock
  4. Ratings Ondine Biomedical Inc.